Emerging gene manipulation strategies for the treatment of monogenic eye disease

Frederick R Burgess*, Hildegard Nikki Hall, Roly Megaw

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Genetic eye diseases, representing a wide spectrum of simple and complex conditions, are one of the leading causes of visual loss in children and working adults, and progress in the field has led to changes in disease investigation, diagnosis, and management. The past 15 years have seen the emergence of novel therapies for these previously untreatable conditions to the extent that we now have a licensed therapy for one form of genetic eye disease and many more in clinical trial. This is a systematic review of published and ongoing clinical trials of gene therapies for monogenic eye diseases. Databases of clinical trials and the published literature were searched for interventional studies of gene therapies for eye diseases. Standard methodological procedures were used to assess the relevance of search results. A total of 59 registered clinical trials are referenced, showing the significant level of interest in the potential for translation of these therapies from bench to bedside. The breadth of therapy design is encouraging, providing multiple possible therapeutic mechanisms. Some fundamental questions regarding gene therapy for genetic eye diseases remain, such as optimal dosing, the relative benefits of adeno-associated virus (AAV)-packaging and the potential for a significant inflammatory response to the therapy itself. As a result, despite the promise of the eye as a target, it has proven difficult to deliver clinically effective gene therapies to the eye. Despite setbacks, the licensing of Luxturna (voretigene neparvovec, Novartis) for the treatment of RPE65-mediated Leber congenital amaurosis (LCA) is a major advance in efforts to treat these rare, but devastating, causes of visual loss.
Original languageEnglish
Pages (from-to)380-391
Number of pages12
JournalAsia-Pacific journal of ophthalmology (Philadelphia, Pa.)
Issue number4
Early online date30 Aug 2022
Publication statusE-pub ahead of print - 30 Aug 2022


  • Humans
  • Genetic therapy - methods
  • Child
  • cis-trans-isomerases - genetics
  • Leber Congenital Amaurosis - genetics - therapy
  • Adult
  • Eye diseases - therapy
  • Genetic vectors
  • Dependovirus - genetics
  • Mutation


Dive into the research topics of 'Emerging gene manipulation strategies for the treatment of monogenic eye disease'. Together they form a unique fingerprint.

Cite this